Drug Trial Radar · NCT04345900
Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2
Last checked: Nov 19, 2026Latest source record: May 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
55
Actual
Start
Apr 5, 2017
Primary completion
Mar 20, 2018
Study completion Apr 20, 2018
Sponsor
- Lead sponsor
- BeyondSpring Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 15, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess the duration of severe neutropenia (DSN) in treatment Cycle 1 in patients treated with docetaxel (75 mg/m2) + plinabulin (5, 10, or 20 mg/m2) or with docetaxel (75 mg/m2) + pegfilgrastim (6 mg). Neutrophils count was to be assessed at baseline (prior to Cycle 1 docetaxel dose) and during Cycle 1 on Days 1, 2, 6, 7, 8, 9, 10, and 15 (pre-dose on dosing days; times equivalent to pre dose on other days).
Conditions
- Chemotherapy-induced Neutropenia
Interventions
PlinabulinDrug
a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).
PegfilgrastimDrug
PEGFILGRASTIM is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.
Primary outcomes
What the sponsor says the trial is designed to measure.
- DSNTime frame: At the end of Cycle 1 (each cycle is 21 days)
Locations
19 sites in 4 countries. Site status is shown where the registry gives one.
Emad Ibrahim, MD, Inc.
Redlands, California
Mid Florida Hematology & Oncology Center
Orange City, Florida
Cancer Center of Middle Georgia
Dublin, Georgia
Hematology/Oncology of the North Shore
Skokie, Illinois
Harbin Medical University Cancer Hospital
Harbin, Harbin, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Jiangsu Cancer Hospital
Nanjing, Jiangsu, China
Medical University 'REAVIZ'
Samara, Russia
SBI of Healthcare "Oncology Dispensary #2" Ministry of Healthcare of Krasnodar Region
Sochi, Russia
Volgograd Regional Clinical Oncology Dispensary
Volgograd, Russia
Municipal Institution Dnipropetrovsk City Multi-functional Hospital
Dnipro, Ukraine
Prykarpatian Clinical Oncological Center
Ivano-Frankivsk, Ukraine
Kherson regional oncological dispensary Communal Institution of Kherson Regional council
Kherson, Ukraine
Regional Municipal Institution "Kryvyy Rig Oncology Dispensary"
Krivói Rog, Ukraine
Kirovograd Regional Oncological Center
Kropyvnytskyi, Ukraine
Kyiv City Clinical Oncology Center
Kyiv, Ukraine
Lviv State Oncological Regional Treatment and Preventive Center
Lviv, Ukraine
Municipal Institution "Sumy Regional Clinical Oncology Dispensary"
Sumy, Ukraine
Zakarpattia Regional Clinical Oncology Center
Uzhhorod, Ukraine
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.